Navigation Links
New Hope to Beat Cancer
Date:3/12/2009

Aurora St. Luke's is one of a few institutions in the world to offer skin cancer clinical trial.

MILWAUKEE, March 12 /PRNewswire/ -- Aurora St. Luke's Medical Center is one of the first institutions in the world to offer a new skin cancer research study that trains the patient's immune system to kill cancer cells.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090303/CG78204LOGO-b)

The Young Tumor-Infiltrating Lymphocyte (Y-TIL) trial is a phase 2 clinical trial being offered with technical support from the National Cancer Institute (NCI) in Bethesda, Md. Milwaukee native Jeff Capstran participated in an earlier stage of this trial at NCI. Capstran had stage-four metastatic melanoma, a diagnosis that few survive, but with small kids at home he was determined to find treatment options.

"I knew that my illness was very serious, but there had to be new opportunities to fight back," Capstran says. "When I found out about the study at NCI, I knew I had to jump at the chance. Today, I am cancer free."

The early results from a similar trial at the NCI are exciting for patients with stage-four metastatic melanoma. Published reports for the trial show a 51 percent response rate.

To qualify, all patients must be diagnosed with stage-four metastatic melanoma. During the trial blood is drawn from the patient, along with a sample of the tumor. The T cells, which are the immune system's killer cells, are extracted from the tumor and re-educated to attack the cancer cells. The patient's normal immune system is then temporarily suppressed using chemotherapy, and the newly trained T cells are returned to the patient. The T cells are expected to survive, replicate and kill the cancer.

The tria
'/>"/>

SOURCE Aurora Health Care
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. Novel Technology Breaks Through Cancer Pain
8. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
9. Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Takeda Pharmaceutical Company Limited ("Takeda") today announced ... of data from a 10-year epidemiology study to ... (U.S.) Food and Drug Administration (FDA), ... Ministry of Health, Labour, and Welfare (MHLW) / ... for pioglitazone containing medicines, including ACTOS (pioglitazone HCl). ...
(Date:8/28/2014)... , Aug. 28, 2014  In anticipation of the upcoming ... being made available for the first time. Industry Overview: ... offers a snapshot of San Diego,s ... Highlighting everything from the latest employment statistics to current venture ... San Diego such a vital part of ...
(Date:8/28/2014)... /PRNewswire-iReach/ -- Academy Leadership, an elite leadership training firm ... a case study highlighting one manager,s experience ... In September and October 2014, Academy Leadership affiliates are ... , Indianapolis , Salt Lake City , ... http://photos.prnewswire.com/prnh/20140828/140814 Leadership training for managers ...
Breaking Medicine Technology:Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 2Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 3Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 4Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 5Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 6New Infographic Published - Overview of Medtech & Life Sciences Industry in San Diego 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 3Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 4Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 5
... , FRIMLEY, England, December 8 ... Measures of Treatment Effectiveness,in the Trial, in Patients With Newly-Diagnosed Disease(1) , ... Later Stages,of the Disease on nilotinib (300mg Twice-Daily and 400mg Twice-Daily) Than ... Well Tolerated; Only a Small Number of Patients,Discontinued Due to Adverse Events(1) ...
... Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical ... cancer, inflammation and autoimmune diseases, today announced data from ... patients with B-precursor acute lymphoblastic leukemia (ALL). The data ... Annual Meeting of the American Society of Hematology (ASH) ...
Cached Medicine Technology:Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 2Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 3Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 4
(Date:8/29/2014)... September yoga month was created by ... and its health benefits. To support this Ekhart Yoga ... "Yoga Month Challenge" , This 4 week guided online ... experienced yogis practice yoga regularly from their own home. ... ' is suitable for all levels, and the dynamic ...
(Date:8/29/2014)... 29, 2014 RBS Reputation Management has brought ... The service is to help those individuals and organizations ... on Scam Book. The service would push down the ranking ... Book complaints fully invisible on Google. , RBS Reputation ... On being asked how company can provide guarantee of results ...
(Date:8/29/2014)... week, the Fed reported an increase in industrial ... to 0.4% while manufacturing output progressed to 1.0%. , ... since February this year. Capacity use has increased by more ... an increase that could be attributed to the boost in ... is a measure of slack across the industries. , Output ...
(Date:8/29/2014)... 2014 Ethane Web Technologies, an ISO ... new service named HTML web design. , The HTML ... tailoring the service, Ethane Web Technologies did extensive research ... company has done its best efforts to make sure ... deliver outstanding results to clients. The company uses ...
(Date:8/29/2014)... well-studied neuroregenerative effect, stimulating neurite extension in ... vitro, and enhancing nerve regeneration following nerve ... of FK506 to stimulate nerve regeneration is ... failure and hypertension, and its considerable cost. ... with other drugs reportedly cause life-threatening infections. ...
Breaking Medicine News(10 mins):Health News:Ekhart Yoga Launches the Yoga Month Challenge 2Health News:RBS Reputation Management Announces a New Online Reputation Management Service 2Health News:LeaseQ Announces That Recent Industrial Production Report Spells Good Things For The Equipment Leasing Industry 2Health News:LeaseQ Announces That Recent Industrial Production Report Spells Good Things For The Equipment Leasing Industry 3Health News:Ethane Web Technologies Launches a New Web Design Service 2
... Highlights ... ... In recognition of Gynecologic Cancer Awareness Month, Planned Parenthood of the Rocky Mountains is ... screenings and treatments to help save their lives., , ,"We see firsthand at our ...
... , , ARLINGTON, Va., ... and Human Services Office of Inspector General (OIG) ignored the ... complex rehab, to seniors and people with disabilities who require ... Medicare Program: Supplier Acquisition Costs and Services" and dated August ...
... WASHINGTON, Sept. 3 Speaker Nancy Pelosi released the following statement ... "Any real change requires the inclusion of a strong public ... option is not included, it would be a major victory for the ... that a public option will keep the insurance companies honest. If someone ...
... VALLEY NATIONAL PARK, STOVE PIPE WELLS, Calif., Sept. 3 Jeff ... , will hike 40 miles per day through California,s Death Valley ... September 5, 2009, Sekerak hikes from Stove Pipe Wells to a ... to demonstrate the superior level of fitness attained through his program, ...
... , BROOMFIELD, Colo., Sept. 3 Embla(R) ... will acquire Covidien,s Sleep Diagnostic business. This includes the sleep diagnostic ... the transaction were not disclosed. Completion of the sale is subject ... entity will form the world,s largest company to focus entirely on ...
... YORK, Sept. 3 As millions of teens head back to school, ... , Teens are at a greater risk of than any ... lack of experience. Many of those crashes could be avoided with proper ... produces free driver education programs. , , NRSF spokesperson ...
Cached Medicine News:Health News:Planned Parenthood Stresses Importance of Regular Checkups During Gynecologic Cancer Awareness Month 2Health News:Federal Study on Power Wheelchair Costs in Medicare Is Misleading and Ignores Costs of Required Services for Beneficiaries 2Health News:Federal Study on Power Wheelchair Costs in Medicare Is Misleading and Ignores Costs of Required Services for Beneficiaries 3Health News:One Man's Answer to the Health Care Crisis: Develop Extreme Fitness 2Health News:Embla(R) Systems Announces the Acquisition of the Sandman(R) Sleep Diagnostic Business from Covidien(R) - Creating the World's Largest Sleep Diagnostic Company 2Health News:Back to School Brings Risks to Young Drivers; Traffic Crashes Leading Cause of Teen Death, Says National Road Safety Foundation 2
P-Series Cystourethroscope Short Bridge, examining...
Short double-horn bridge for insertion of instruments...
Designed for accurate articulation of flexible devices....
... Used for stone manipulation and removal in the ... basket to retain its shape following extreme torsion. ... capture by allowing the basket to open at ... stone. The tipless design reduces the likelihood of ...
Medicine Products: